Clinical use of Cryoprecipitate
- Arthur J Silvergleid, MD
Arthur J Silvergleid, MD
- Section Editor — Transfusion Medicine
- Affiliate Associate Professor, Department of Pathology and Cell Biology
- University of South Florida, College of Medicine
- Medical Director, OneBlood, Inc.
Cryoprecipitate (Cryoprecipitated antihemophilic factor [AHF]; cryo) is the insoluble material that comes out of solution after plasma is frozen and thawed at 4°C (between 1 and 6°C). It is rich in certain plasma proteins, especially fibrinogen.
This topic will discuss the clinical use of Cryoprecipitate. Use of other plasma products and plasma derivatives is discussed in separate topic reviews:
●Fresh Frozen Plasma (FFP) and other plasma products – (See "Clinical use of plasma components".)
●Plasma derivatives including coagulation factor concentrates – (See "Plasma derivatives and recombinant DNA-produced coagulation factors".)
●Fibrin sealant – (See "Fibrin sealant".)
- O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126:11.
- Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev 2009; 23:177.
- Hesselvik F, Brodin B, Carlsson C, et al. Cryoprecipitate infusion fails to improve organ function in septic shock. Crit Care Med 1987; 15:475.
- Infusion rate
- Dosing interval
- CLINICAL USES
- Overview of uses
- Inherited disorders of fibrinogen
- Impaired hemostasis in liver disease
- Disseminated intravascular coagulation
- Uremic bleeding
- CONDITIONS FOR WHICH CRYOPRECIPITATE IS INEFFECTIVE
- RISKS AND ADVERSE EVENTS
- SUMMARY AND RECOMMENDATIONS